Reporting Quality of Drug Safety Systematic Reviews: A Cross-Sectional Study
September 2018
in “
Value in Health
”
TLDR Cochrane and non-Cochrane drug safety reviews report well in PRISMA but poorly in PRISMA harms, with non-Cochrane needing improvement.
In 2018, a cross-sectional study was conducted to examine the reporting quality of drug safety systematic reviews. The study included 120 systematic reviews, 60 from Cochrane and 60 non-Cochrane. The reporting quality was assessed using PRISMA and PRISMA harms checklist. The results showed that Cochrane systematic reviews had a higher overall score for the PRISMA checklist (24.8±2.1) compared to non-Cochrane systematic reviews (23.1±2.6). However, both types of reviews had low scores on the PRISMA harms checklist, with no significant difference between the two (4.4±2.5 vs. 3.9±2.4). The study concluded that while both Cochrane and non-Cochrane systematic reviews had good reporting in PRISMA, they both had poor reporting in PRISMA harms. The type of systematic review and type of journal were identified as factors associated with the reporting quality. The study suggested that the reporting quality of non-Cochrane systematic reviews in PRISMA harms should be improved in the future.
